Chiron suffers exchange rate dampener in first quarter
This article was originally published in Clinica
Executive Summary
Excluding the effect of foreign currency changes, Chiron's product sales would have risen 9% in the first quarter, above the actual 5% increase to $251 million. The diagnostics turnover of the US biotechnology company was up a strong 10%, supported by sales of bDNA probe tests which more than doubled to $13 million compared with $6 million in the previous year.